|
|
Volumn 88, Issue 2, 2012, Pages 112-115
|
|
Maintaining cost-effective access to antiretroviral drug therapy through a collaborative approach to drug procurement, consensus treatment guidelines and regular audit: The experience of London HIV commissioners and providers
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ABACAVIR PLUS LAMIVUDINE;
ANTIRETROVIRUS AGENT;
ATAZANAVIR PLUS RITONAVIR;
EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;
EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;
ANTIRETROVIRAL THERAPY;
ANTIVIRAL THERAPY;
CARDIOVASCULAR RISK;
CONFERENCE PAPER;
CONSENSUS DEVELOPMENT;
COST CONTROL;
COST EFFECTIVENESS ANALYSIS;
DRUG COST;
HEALTH CARE COST;
HEALTH CARE QUALITY;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
LEADERSHIP;
MEDICAL AUDIT;
PHARMACIST;
PHYSICIAN;
PRESCRIPTION;
PRIORITY JOURNAL;
PRODUCTIVITY;
TREATMENT OUTCOME;
UNITED KINGDOM;
ANTI-RETROVIRAL AGENTS;
ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE;
COMMISSION ON PROFESSIONAL AND HOSPITAL ACTIVITIES;
COOPERATIVE BEHAVIOR;
COST-BENEFIT ANALYSIS;
DELIVERY OF HEALTH CARE;
DRUG PRESCRIPTIONS;
GUIDELINE ADHERENCE;
HEALTH POLICY;
HIV INFECTIONS;
HUMANS;
LONDON;
|
|
EID: 84863413210
PISSN: 13684973
EISSN: 14682044
Source Type: Journal
DOI: 10.1136/sextrans-2011-050438 Document Type: Conference Paper |
|
Times cited : (9)
|
|
References (7)
|
